The Other Press, February 19, 1987

<p>Energy profile (in kcal.mol^-1) of face-on path for Erlotinib bioactivation by the Cpd I model of CYP3A4 and 1A2 in the gas and solvent phases.</p

Additional file 5: Table S3. of Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer

PCR Primers of ER group genes and reference genes. (DOC 32 kb

Additional file 3: Table S2. of Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer

Genes and probe sets used to characterize subgroups within ER–/PgR+/HER2– phenotype. (DOC 40 kb

Additional file 1: Figure S1. of Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer

The study flowchart diagram. FDUSCC, Fudan University Shanghai Cancer Center; NCT, Neoadjuvant chemotherapy; SEER, Surveillance, Epidemiology and End Results program. (PPTX 111 kb

Additional file 8: Table S5. of Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer

Survival benefit from adjuvant endocrine therapy in 55 out of the 64 ER–/PgR+/HER2– cases. (DOC 30 kb

Kaplan–Meier estimates of breast cancer-specific survival and overall survival according to different treatments.

<p><b>A: Breast cancer specific survival, B: Overall survival.</b> The table below lists the results of pairwise comparisons of breast cancer-specific survival and overall survival between different treatment groups.</p

Cox proportional hazard regression model of Breast Cancer-Specific Survival comparing reconstruction method to mastectomy alone stratified by family income.

<p><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0082807#pone-0082807-t002" target="_blank">Table 2</a>.^a Adjusted by Cox proportional hazards models including all factors, as categorized in </p

Cox proportional hazard regression model of Overall Survival.

<p><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0082807#pone-0082807-t003" target="_blank">Table 3</a>.^a Adjusted by Cox proportional hazards models including all factors, as categorized in </p><p>^b Including American Indian/AK Native, Asian/Pacific Islander.</p><p>^c Including divorced, widowed, single (never married),separated.</p><p>% of individuals having over a 12th grade education level; Low indicates a county with less than 78.0% (including 78.0%) of individuals having over a 12th grade education level. (78.0% is the median of all county education data studied).^d High indicates a county with greater than 78.0</p><p>^e Grade are coded as followings: Well differentiated; Grade I; Moderately differentiated; Grade II; Poorly differentiated; Grade III; Unknown.</p><p>^f ER: Estrogen Receptor; PR: Progesterone Receptor.</p

Demographic and tumor characteristics of the study sample.

<p>^a P value of Chi-square test comparing the mastectomy only and the pooled reconstruction groups.</p><p>^b P value of Chi-square test comparing the autologous only and implant only groups.</p><p>^c Including American Indian/AK Native, Asian/Pacific Islander.</p><p>^d Including divorced, widowed, single (never married),separated.</p><p>% of individuals having over a 12th grade education level; Low indicates a county with less than 78.0% (including 78.0%) of individuals having over a 12th grade education level. (78.0% is the median of all county education data studied).^e High indicates a county with greater than 78.0</p><p>^f Grade are coded as followings: Well differentiated; Grade I; Moderately differentiated; Grade II; Poorly differentiated; Grade III; Unknown.</p><p>^g ER: Estrogen Receptor; PR: Progesterone Receptor.</p

The Effect of Laterality and Primary Tumor Site on Cancer-Specific Mortality in Breast Cancer: A SEER Population-Based Study

<div><p>Background</p><p>Reduced overall survival has been observed in patients with left-sided versus right-sided breast cancer due to cardiac toxicity after radiotherapy. However, the effect of laterality and primary tumor site on breast cancer-specific mortality (BCSM) remains unclear.</p><p>Patients and Methods</p><p>We analyzed data from 305,443 women ages 20- to 79-years-old diagnosed with breast cancer between 1990 and 2009. The data were obtained from the population-based Surveillance, Epidemiology, and End Results (SEER) program of the U.S. National Cancer Institute. The survival outcomes with regard to laterality and primary tumor site were compared using univariate and multivariate (Cox proportional hazards regression model) methods.</p><p>Results</p><p>In the multivariate analysis, BCSM was affected by the primary tumor site (P<0.0001) but not laterality (P = 0.331). The combined effect was piecewise: using the left upper-outer quadrant as the reference, the BCSM hazard ratio (HR) was not significant in the right upper quadrant (P = 0.755) and the right central portion (P = 0.329). The BCSM HR was slightly increased in the left central portion as well as the left and right lower-outer quadrants (HRs from 1.136 to 1.145; P<0.0001). The BCSM HR was significantly increased in the upper-inner and lower-inner quadrants (HRs from 1.242 to 1.372; P<0.0001) on both sides. Laterality only impacted BCSM in patients with breast cancer located in the central portion (HR, 1.100; P = 0.013, using the right side as the reference).</p><p>Conclusion</p><p>Patients with tumors in the upper-outer quadrant of both sides and the right central portion have a better prognosis than patients with tumors at other locations. Laterality is not regarded as a prognostic factor in breast cancer.</p></div